Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Frisoni, Giovanni B. ; Festari, Cristina ; Massa, Federico ; Cotta Ramusino, Matteo ; Orini, Stefania ; Aarsland, Dag ; Agosta, Federica ; Babiloni, Claudio ; Borroni, Barbara and Cappa, Stefano F. , et al. (2024) In The Lancet Neurology 23(3). p.302-312
Abstract

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history... (More)

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet Neurology
volume
23
issue
3
pages
11 pages
publisher
Lancet Publishing Group
external identifiers
  • pmid:38365381
  • scopus:85185269773
ISSN
1474-4422
DOI
10.1016/S1474-4422(23)00447-7
language
English
LU publication?
yes
id
baafb178-b79c-4bff-a471-33dc841956d7
date added to LUP
2024-03-27 09:23:12
date last changed
2025-01-31 22:33:20
@article{baafb178-b79c-4bff-a471-33dc841956d7,
  abstract     = {{<p>The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.</p>}},
  author       = {{Frisoni, Giovanni B. and Festari, Cristina and Massa, Federico and Cotta Ramusino, Matteo and Orini, Stefania and Aarsland, Dag and Agosta, Federica and Babiloni, Claudio and Borroni, Barbara and Cappa, Stefano F. and Frederiksen, Kristian S. and Froelich, Lutz and Garibotto, Valentina and Haliassos, Alexander and Jessen, Frank and Kamondi, Anita and Kessels, Roy PC and Morbelli, Silvia D. and O'Brien, John T. and Otto, Markus and Perret-Liaudet, Armand and Pizzini, Francesca B. and Vandenbulcke, Mathieu and Vanninen, Ritva and Verhey, Frans and Vernooij, Meike W. and Yousry, Tarek and Boada Rovira, Mercè and Dubois, Bruno and Georges, Jean and Hansson, Oskar and Ritchie, Craig W. and Scheltens, Philip and van der Flier, Wiesje M. and Nobili, Flavio}},
  issn         = {{1474-4422}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{302--312}},
  publisher    = {{Lancet Publishing Group}},
  series       = {{The Lancet Neurology}},
  title        = {{European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders}},
  url          = {{http://dx.doi.org/10.1016/S1474-4422(23)00447-7}},
  doi          = {{10.1016/S1474-4422(23)00447-7}},
  volume       = {{23}},
  year         = {{2024}},
}